An experimental Satsuma Pharmaceuticals treatment for acute migraine has failed a late-stage clinical trial, dealing a setback to the company’s plans to offer another therapeutic option to the millions of people who suffer from the condition.
In Phase 3 results released Thursday, South San Francisco-based Satusuma (NASDAQ: STSA) reported that preliminary data showed both doses of its experimental treatment, STS101, led to improvement in measures of pain and other symptoms. But those differences, compared to a placebo, were not enough to be statistically significant.
Shares of Satsuma plummeted on the news, opening Thursday at $4.80 apiece, down nearly 80 percent... Read more »
Author: Frank Vinluan
Date : 2020-09-10T14:32:50.000Z